The prophylactic vaccination studies in animals showed that, in contrast to natural infection, protective immune responses to gastric helicobacter can be induced. The question was then addressed whether vaccination could be used to eliminate existing infection. Oral immunisation with helicobacter sonicates 12 or recombinant urease B subunit 13 together with cholera toxin eliminated chronic H felis infection in mice and protected against subsequent H felis challenge. 13 Therapeutic immunisation also was successful in ferrets infected with H mustelae. 14 In their study Ghiara et al investigated the feasibility of the therapeutic use of H pylori antigens as vaccines against chronic H pylori infection. Importantly, they also test the ability of a genetically detoxified mutant of the heat labile toxin of Escherichia coli (LTK63) 15 to act as a mucosal adjuvant. Their study shows for the first time that oral administration of either H pylori sonicates or recombinant proteins (VacA and CagA), together with LTK63, successfully eradicates H pylori infection in mice. The treated mice remained non-infected for at least three months after therapeutic vaccination, confirming long term persistence of eradication rather than suppression of the chronic infection. Importantly, Ghiara et al also show that the therapeutic vaccine both eradicates infection and confers protection against subsequent challenge.
Successful mucosal vaccination requires strong adjuvants to improve the poor immunogenicity of coadministered antigens. A key role of mucosal adjuvants is likely to be the stimulation of T helper-2 (Th2) type mucosal responses. 16 17 The inherent toxicity of the mucosal adjuvants cholera toxin and heat labile enterotoxin (LT) has been a major limitation for their use as vaccines in humans. Recent clinical studies in H pylori infected human volunteers testing the safety and immunogenicity of recombinant H pylori urease showed that the coadministration of LT was associated with a high incidence of diarrhoea. 18 The use of genetically detoxified heat labile enterotoxins such as LTK63 15 is likely to circumvent this problem. LTK63 has a single amino acid substitution (Ser to Lys in position 63) which destroys its ADP ribosylating toxic activity. 15 Non-toxic LTK63 has been used success- fully as a mucosal adjuvant in animal models to induce antigen specific humoral responses 19 and measles virus specific cytotoxic lymphocyte responses. 20 The demonstration by Ghiara et al that the genetically detoxified mutant of the heat labile E coli enterotoxin is also suitable for therapeutic oral vaccination against H pylori is an important development for its future clinical use.
An understanding of the mechanisms involved in the induction of protective mucosal responses to H pylori is important for future clinical use of prophylactic and therapeutic vaccines. As discussed by Ghiara et al, the role of the adjuvant in therapeutic vaccination may be to change the nature of the chronic gastric Th1 type tissue damaging response to a Th0 or Th2 protective response. In the H felis mouse model stimulation of Th2 responses has been associated with a reduction in both bacterial load 21 and gastric inflammation. 22 Down-regulation of Th1 responses by neutralisation of interferon-in H felis immunised mice resulted in unmasking of both splenic and gastric interleukin 4 (IL-4) Th2 responses. 22 Adoptive transfer of splenic T cells from mice after immunisation and challenge and of in vitro generated H felis specific Th2 cell lines also reduced the bacterial load of H felis after challenge in naive recipients. 21 Consistent with these observations, Mohammadi et al also found that IL-4 knockout mice had an increased bacterial load of H felis compared with wild type controls. 21 Ghiara et al, while confirming that chronic H pylori infection in the mouse model induces a Th1 response, did not examine the eVector mechanisms contributing to the success of therapeutic vaccination. They speculate, however, that therapeutic vaccination induces activation of Th0 or Th2 responses which in turn trigger bacterial eradication. Current evidence suggests that gastric Th1 responses predominate in humans with chronic H pylori infection. 23 24 It remains to be investigated whether the human gastrointestinal responses can be similarly modified. If so, given the availability of non-toxic mucosal adjuvants, 15 therapeutic vaccines may prove to be a novel means of eradicating H pylori and a therapeutic alternative to the use of antibiotic based regimens. 
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